FAQs
Corporate FAQs
Our corporate headquarters is in Fort Worth, Texas
Our shares are traded on NASDAQ Global Market under the stock symbol ACTU
Actuate was incorporated on January 16, 2015
Actuate went public on August 13, 2024
Our fiscal year begins January 1st and ends December 31st
Actuate does not anticipate issuing dividends on its common stock in the foreseeable future.
Our independent auditors have been KMJ Corbin & Company LLP.
Our corporate counsel is Baker & Hostetler LLP
Please visit www.actuatetherapeutics.com or email investors@actuatetherapeutics.com
Our SEC filings are listed on the SEC’s website, www.sec.gov. You may find this information on our investor relations website at www. actuatetherapeutics.com, under ‘SEC Filings’.
Broadridge Corporate Issuer Solutions, LLC
51 Mercedes Way
Edgewood, NY 11717
shareholder@broadridge.com
844-998-0339 or 303-562-9304
Scientific FAQs
- Erlaglusib is a novel GSK-3β inhibitor that targets multiple molecular pathways that promote tumor growth, and resistance to traditional cancer treatments like chemotherapy. In benchmarking studies, elraglusib has shown higher cell-based potency compared to other GSK-3β inhibitors tested in cancer cell lines.
- Elraglusib is emerging as a mediator of anti-tumor immunity by inhibiting multiple immune checkpoints, activating and expanding T and NK cell function, altering cytokine dynamics, and altering immune system maturation after treatment.
- Initial clinical experience focused on advanced cancers where drug resistance was thought to be mediated by NF-κB and would thus be a candidate for chemotherapy enhancement using a GSK-3β inhibitor.
- Clinical development strategy and choice of cancer indications to target are based on extensive pre-clinical studies, understanding the MOA of GSK-3β in cancer, and data from the clinical trials evaluating elraglusib to date including tumors where we saw consistent evidence of antitumor activity such as mPDAC and Ewing sarcoma. The plan continues to be informed by observations of antitumor immune system response mediated by elraglusib as well as bed-to-bench side observations that support this emerging MOA. The development of an oral dosage form will further expand the types of cancers that may benefit from elraglusib treatment.
- It’s a multifaced approach to cancer treatment. It not only targets molecular pathways in cancer cells but also impacts the TME and immune response. These activities could occur in one type of cancer or potentially in different types of cancer, thus increasing the portfolio of cancer indications amenable to elraglusib treatment. Elraglusib kinase profiling suggests minimal off-target effects on housekeeping kinases. This comprehensive approach potentially allows for better tumor control with manageable side effects.
- Elraglusib targets a well-credentialed target in advanced cancer, GSK-3β, that may contribute unique antitumor effects to the armamentarium of cancer agents. Elraglusib monotherapy in oral liquid form is well-tolerated by certain healthy volunteers when given with food and may lend itself well for use in combination regimens. Historically, this is a successful approach to treating advanced, refractory cancers. Some potential benefits to patients receiving elraglusib based on pre-clinical and early clinical observations may be tumor shrinkage and prolonged survival, but these remain to be demonstrated in controlled randomized clinical studies.
- Elraglusib monotherapy appears to have a favorable safety profile as a single agent in the patients studied to date. In combination with chemotherapy, no new side effects have been observed in the combination cohorts although some chemotherapy side effects may be exacerbated by the addition of elraglusib. However, the studies evaluating combination safety profiles are still ongoing and will need to be evaluated and discussed with regulators for each drug combination separately. Like all medications, some side effects may occur, which will be closely monitored and managed by healthcare professionals.
- Elraglusib is undergoing clinical trials in various indications for regulatory approval and is not yet commercially available. Patients interested in accessing the drug through clinical trials should consult with their healthcare provider or clinical trial coordinators for information on eligibility and availability.
- GSK-3β is a complex regulator of numerous cellular functions implicated in various diseases, including cancer. GSK-3β is a constitutively active adaptor kinase that regulates cellular/tissue signaling based on the genotypic and phenotypic alterations in that cell and therefore shows little or no activity in most adult, quiescent tissue.
- In addition to cancer, GSK- 3β dysregulation has been linked to a wide range of diseases, including neurodegenerative disorders, inflammatory conditions, and fibrosis.
- In cancer, GSK- 3β is understood to be an essential positive regulator of nuclear factor kappa B (NF-κB) mediated viability and chemo-resistance of cancer cells, making it a potential therapeutic target. Additionally, GSK-3β regulates the expression of immune modulators such as pro-inflammatory cytokines and checkpoint molecules in tumor and immune cells. These effects could also be related to inhibition of NF-κB in immune or TME cells or could be through other pathways.